The serotonin transporter gene (SLC6A4, MIM 182138) is a candidate gene in autistic disorder based on neurochemical, neuroendocrine studies and the efficacy of potent serotonin transporter inhibitors in reducing ritualistic behaviors and related aggression. An insertion/deletion polymorphism (5-HTTLPR) in the promoter region and a variable number of tandem repeat polymorphism (VNTR) in the second intron, were previously identified and suggested to modulate transcription. Six previous family-based association studies of SLC6A4 in autistic disorder have been conducted, with four studies showing nominally significant transmission disequilibrium and two studies with no evidence of nominally significant transmission disequilibrium. In the present study, TDT was conducted in 81 new trios. A previous finding of transmission disequilibrium between a haplotype consisting of the 5-HTTLPR and intron 2 VNTR was replicated in this study, but not preferential transmission of 5-HTTLPR as an independent marker. Because of inconsistent transmission of 5-HTTLPR across studies, SLC6A4 and its flanking regions were sequenced in 10 probands, followed by typing of 20 single nucleotide polymorphisms (SNPs) and seven simple sequence repeat (SSR) polymorphisms in 115 autism trios. When individual markers were analyzed by TDT, seven SNP markers and four SSR markers (six SNPs, 5-HTTLPR and the second intron VNTR from promoter 1A through intron 2 of SLC6A4, one SSR from intron 7 of SLC6A4, one SNP from the bleomycin hydrolase gene (BLMH, MIM 602403) and one SSR telomeric to BLMH) showed nominally significant evidence of transmission disequilibrium. Four markers showed stronger evidence of transmission disequilibrium (TDT max P = 0.0005) than 5-HTTLPR.
Introduction
Autistic disorder is characterized by qualitative impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, the presence of developmental abnormalities by 3 years of age, and evidence that it is strongly genetic. [1] [2] [3] [4] However, due to genetic (locus and allelic) and phenotypic heterogeneity, multiplicative inheritance, and number of loci involved, single major locus effects are unlikely and the contribution of each locus to risk is likely to be small relative to the overall increased risk to siblings and monozygotic twins. 5, 6 No specific autism susceptibility variant has been identified and confirmed. Several lines of evidence, such as increased whole blood serotonin level in autism probands 7 and the efficacy of potent serotonin transporter inhibitors in reducing rituals and aggression [8] [9] [10] led us to consider human serotonin transporter gene SLC6A4 as a primary candidate in autism.
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SLC6A4 was cloned and localized to chromosome 17q11.1-q12 12 and linkage mapped between D17S58 and D17S73. 13 Shen and colleagues 14 physically mapped SLC6A4 proximal to CPD (Carboxypeptidase D; MIM 603102) and NF1 (Neurofibromatosis, Type I; MIM 162200). SLC6A4 contains a 630-amino acid open reading frame and consists of 15 exons including noncoding exon 1A and exon 1B. 15, 16 Exon 1B was found to be located approximately 14 kb downstream of exon 1A and 737 bp upstream of exon 2 and to be present in some but not all transcripts. 16 Two common polymorphisms, an insertion/deletion polymorphism (5-HTTLPR) in the promoter region and a variable number of tandem repeat (VNTR) polymorphism in intron 2, were previously identified and suggested to modulate the expression of serotonin transporter at the transcriptional level. [17] [18] [19] [20] These polymorphisms and a 3ЈUTR SNP have been studied in several neuropsychiatric disorders and personality quantitative trait loci (QTLs), including response to antidepressant treatment. [21] [22] [23] [24] A series of transmission/disequilibrium test (TDT) studies using 5-HTTLPR and VNTR to determine whether SLC6A4 contributes to susceptibility to autistic disorder failed to reveal any consistent evidence of transmission of an allele or haplotype. [25] [26] [27] [28] [29] [30] Using the TDT, evidence of preferential transmission of the short variant of 5-HTTLPR was found by Cook and colleagues 25 and preferential transmission of the long allele was reported by others. 26, 29, 30 No evidence of family-based association was reported by Maestrini and colleagues 27 or Persico and colleagues. 28 A casecontrolled study has also shown no evidence of association between 5-HTTLPR and autistic disorder. 31 Although previous LD mapping results in complex genetic disorders have followed genome-wide linkage studies, [32] [33] [34] [35] mapping of candidate susceptibility variants based on function may be possible. In addition, although initial genome-wide scans in autism did not provide support for linkage at SLC6A4, extension of the International Molecular Genetic Study of Autism Consortium (IMGSAC) study by inclusion of more families led to a multipoint MLS of 2.34 and single point MLS score of 3.6 at the SLC6A4 intron 2 VNTR. 36 To further investigate whether SLC6A4 may be a locus contributing to susceptibility for autism, a replication study of the original marker (5-HTTLPR) and haplotype (5-HTTLPR/intron 2 VNTR) TDT finding 25 was conducted. A denser map of polymorphisms was established by screening approximately 38 kb of genomic sequence of 10 unrelated autism probands for mutation by direct sequencing of PCR products. One hundred and fifteen autism trios were typed for 20 SNPs and seven SSR markers within or flanking the SLC6A4 gene and a TDT was performed for each marker.
Methods

Subjects
Consecutive subjects consenting to participate in a family-based association study of candidate loci for autistic disorder were studied between January 1995 and July 1999 at the University of Chicago Developmental Disorders Clinic and between October 1997 and September 1998 at the Laboratory for Research on the Neuroscience of Autism, Children's Hospital Research Center, La Jolla. Institutional Review Board approval was provided at each institution for the study. In the current analysis, inclusion criteria were chronological age greater than 30 months of age; Autism Diagnostic Interview-Revised (ADI-R) 37 classification of autistic Molecular Psychiatry disorder; Autism Diagnostic Observation Schedule (ADOS) 38 classification of autistic disorder or autistic spectrum disorder; DSM-IV 39 diagnosis of autistic disorder: (1) by a child psychiatrist or child neurologist and (2) by a clinical psychologist; availability of sufficient DNA or blood for DNA extraction from each proband and both parents; negative molecular diagnostic test for Fragile X syndrome (FRAXA); negative Wood's lamp examination for tuberous sclerosis, and absence of focal neurological signs or a specific syndrome (other than autistic disorder or mental retardation); non-verbal IQ greater than or equal to 35; and non-verbal mental age greater than or equal to 18 months. Exclusion criteria were any specific diagnosis (eg 15q11-q13 duplication, Rett syndrome, Angelman syndrome). A proband was excluded if any of the inclusion criteria were absent or if any exclusion criterion was present. The sample of families meeting full inclusion criteria includes six affected-sibling pairs and one family with three affected children in which one of the affected siblings was randomly chosen for generation of a single parent-child trio for each family. The sample consisted of 115 trios (99 assessed in Chicago and 16 assessed in San Diego), consisting of a proband who met all inclusion criteria and did not meet any exclusion criteria, and both parents. Of the probands, 98 were male and 17 were female. Ninetyfour were Caucasian, seven were African-American, eight were Asian-American, and six were Hispanic. Chronological age was 84.7 ± 62.1 (mean ± SD) months. Nonverbal IQ was 77.9 ± 24.5. Based on the ADI-R overall level of language code, 71 of the 115 probands used functional language with at least three word phrases on a daily basis; 23 probands used single words or simple phrases on a daily basis without flexible three-word phrases; and 21 probands did not speak on a daily basis or used fewer than a total of five words. ADI-R scores were as follows: social, 22.0 ± 4.9; communication, 14.8 ± 4.2; and restricted and repetitive behaviors, 6.6 ± 2.3. ADOS criteria for autistic disorder were met by 108 subjects and autistic spectrum disorder criteria were met by the other seven subjects. Thirty-four of the 115 trios included in the current report were included in the original report of familybased association between SLC6A4 and autistic disorder. 25 The samples in the original report not included in the fine mapping have been set aside until functional variants replicated to contribute to susceptibility to autistic disorder have been confirmed due to the small amount of DNA remaining. Two probands were also included in the IMGSAC linkage analysis (2001).
PCR and direct sequencing for mutation screen Sixtyfive pairs of primers were designed to screen approximately 38 kb genomic DNA sequence of SLC6A4 (Table  1) . Ten unrelated autism probands were selected for direct sequencing of individual subjects. Eight of ten selected subjects had at least one short variant of 5-HTTLPR transmitted from a heterozygous parent. The 5-HTTLPR genotype distribution was six short/short, two short/long, and two long/long. A control pool, con- or AmpliTaq Gold  DNA Polymerase (Applied Biosystems, Foster City, CA, USA); optional 0.5 M GC-melt (Clontech, Palo Alto, CA, USA). PCR products were separated on 2% agarose gels, and excised fragments were extracted using the QIAquick Gel Extraction Kit (Qiagen, Valencia, CA, USA). Cycle sequencing was performed using the ABI PRISM BigDye  Terminator Cycle Sequencing Ready Reaction Mix (Applied Biosystems). Sequencing fragments were separated by capillary electrophoresis and detected via laserinduced fluorescence on an ABI PRISM 3700 Genetic Analyzer using POP6 polymer (Applied Biosystems) in the GENOCORE shared facility at the University of Chicago.
FP-TDI assay Twenty SNP markers (Table 2) were typed using fluorescent polarization-template directed dye-terminator incorporation assay (FP-TDI). 40 FP-TDI was performed by: (i) PCR amplification of a fragment containing the SNP of interest; (ii) removal of unincorporated primers and dNTPs; (iii) single base extension reaction. PCR primers were designed to amplify a small fragment (100-300 bp) containing the SNP. An internal extension primer whose 3Ј end annealed immediately upstream of the SNP was designed. For step (i), PCR reactions were performed in a 5 l volume containing 25 ng genomic DNA, 0.1 M of each primer, 25 M of each dNTP, 2.5 Genotyping of SSR polymorphisms PCR products were prepared for injection on the ABI PRISM 310 Genetic Analyzer (Applied Biosystems), in a final volume of 11.5 l consisting of 10 l deionized formamide, 0.5 l GS500 size standard, and 1.0 l PCR products. Products were separated by POP4 polymer and sized with 310 GeneScan Analysis 2.02 and Genotyper 2.5 software (Applied Biosystems).
Whole blood serotonin analysis Whole blood serotonin (WB5HT) was analyzed by HPLC with fluorometric detection after removal of proteins by acid precipitation with percholoric acid as previously reported. 41 It was only feasible to collect WB5HT at the University of Chicago site. Subjects were excluded from analysis of WB5HT if they were taking psychotropic medication or any other medication affecting serotonin levels.
Statistical analysis Genotype distributions in the patient and parent data were assessed for departures from expectations based on Hardy-Weinberg equilibrium using CAL software generated at the University of Chicago for testing HWE and comparing allele and genotype frequency distributions among groups. TDT values were calculated for complete trios only using the sibFtdt program of ASPEX version 2.3. Haplotype TDT analysis for 5-HTTLPR/intron 2 VNTR was performed as in the original study; when there was phase ambiguity due to each individual in a trio being heterozygous at a marker, each haplotype was considered to be equally likely. 11 .58, 4 df, P = 0.021; see Table 3 ).
Results
Replication
Mutation screening and new marker identification
There was no evidence for a nonsynonymous mutation or definite splicing mutation in the screened sequence of SLC6A4. However, during the mutation screening process, novel sequence was elucidated between exon 1A and exon 1B by long range PCR (AF298814). As a result, the distance between exon 1A and exon 1B was determined to be between 12 674 and 12 719 bp depending on the length of a trinucleotide repeat identified within intron 1A (GDB: 10450313). Twenty-three novel SNPs (Table 2 and others deposited in dbSNP as HTT# under the handle LDN) and three novel SSR markers were identified. The second and third SSR markers (GDB: 10450559 and 10797365) were identified from working draft sequence (NTF024938.1). During the study, several sequence dif- ferences in the 4th and 5th exon-intron splice regions were found between published sequence (X76755) and sequencing data in this study. Findings were verified by sequencing five unrelated control subjects as well as comparing the sequences with published mRNA sequence (GenBank NMF001045) and working draft reference sequence (NTF024938.1). In the corrected sequence, GCGCCACGTAAGTCAC is deleted from the 3Ј end of X76755 exon 4, TTCACCCCAG is deleted from the 5Ј end of exon 5 and CTCTGGCAAG is added to the 3Ј end of exon 5. The new exon 4 flanking sequence has been deposited to GenBank (AF233399). A cryptic splice site was identified in the donor site of intron 4, which was located 10 bp downstream of the splice site consistent with the reference mRNA sequence. This downstream cryptic splice site has as high a prediction score for splicing as the original one (cryptic vs original 0.99 vs 0.98) according to the Splice Site Prediction program (http://www.fruitfly. org/seqFtools/splice.html). One SNP (HTTSNP21, see Table 2 ) occurring on this cryptic splice site was observed from one of our screening subjects. However, there is no experimental evidence of alternative splicing of intron 4.
TDT analysis Twenty SNPs from SLC6A4 and the larger flanking regions were typed using FP-TDI (Table  2 ). Seven SNP markers had nominally significant evidence for transmission disequilibrium as well as 5-HTTLPR and the intron 2 VNTR (Table 2, Figure 1 ). These ranged from BLMH to intron 2 of SLC6A4, with the strongest evidence for transmission disequilibrium from the 5Ј flanking region of exon 1B (TDT max P = 0.0005) to intron 2. Two of the microsatellite multiallelic TDTs within intron 7 of SLC6A4 (HTT-GAAA; GDB: 10797365) and distal to BLMH (LDN-CTT; GDB: 10450559) were nominally significant, but not the microsatellite within the region where several SNP TDTs were nominally significant. Twenty probands had a WB5HT level greater than 250 ng ml −1
. In this Table 2 .
Molecular Psychiatry subset, 10 heterozygous parents transmitted a 5-HTTLPR short allele and eight heterozygous parents transmitted a 5-HTTLPR long allele; ten heterozygous parents transmitted a SNP9 C allele and eight heterozygous parents transmitted a SNP9 T allele.
Discussion
This study was designed to: (1) test 5-HTTLPR and 5-HTTLPR/intron 2 VNTR for transmission disequilibrium in a new sample of 81 autism trios; (2) screen SLC6A4 for variants in autism probands; (3) identify polymorphic markers in SLC6A4 and the flanking region; (4) determine the pattern of transmission disequilibrium in a larger sample as a preliminary approach to fine mapping of a possible susceptibility variant in the region.
Replication attempt in 81 new trios with unrelated autism probands
Although support was not found for 5-HTTLPR in the replication sample, the 5-HTTLPR/intron 2 haplotype TDT was nominally significant. As mentioned in the original publication, if the 5-HTTLPR was solely contributing to risk for autistic disorder, one would not expect the haplotype to have stronger evidence of transmission in two studies. Two other studies have reported 5-HTTLPR/intron 2 haplotype transmission and not found significant transmission disequilibrium. 26, 27 Mutation screening of primary DNA sequence of SLC6A4 Glatt and colleagues 42 found no SLC6A4 amino acid variants that occurred in more than eight out of 900 chromosomes from a control population. 42 Several studies screened SLC6A4 by sequencing DNA of affective disorder and obsessive-compulsive disorder (OCD) probands along with control subjects and did not identify any amino acid variants. [43] [44] [45] However, there has been no previous report of mutation screening of SLC6A4 in autistic disorder. Over 38 kb of SLC6A4 and its immediate flanking regions that included all SLC6A4 exons, most of the introns, and both promoter regions were screened by bi-directional sequencing for 5-10 unrelated autism probands (all 10 were completely screened for all exons and immediate exon-intron boundaries). Eight out of 10 screened probands with autism were selected based on transmission of at least one short 5-HTTLPR variant from a heterozygous parent, since that allele had been preferentially transmitted in the first study of 5-HTTLPR in the laboratory. 25 No variants were found in the coding region of SLC6A4 in the 10 screened probands with autism, suggesting that alteration in the primary structure of SLC6A4 is not likely to contribute to autistic disorder susceptibility. However, it must be noted that there were gaps in coverage of the gene and that a functional variant may have been missed on chromosomes with long 5-HTTLPR alleles, since only six chromosomes with a long 5-HTTLPR allele were screened by sequencing.
Identification of polymorphisms Twenty-three novel SNP markers as well as three polymorphic microsatellite markers (GDB: 10450559, 10450313 and 10797365) were identified during the mutation screening of SLC6A4. Screening 20 chromosomes limited the identification of less frequent polymorphisms that would have been found in screening of a larger population. 46 However, it is unlikely that a polymorphism not detected with this sample size would have contributed substantially to the original nominally positive transmission disequilibrium between markers at SLC6A4 and autistic disorder.
Examination of transmission disequilibrium of SLC6A4 markers Previously, preferential transmission of the short variant of 5-HTTLPR and a haplotype consisting of 5-HTTLPR and the intron 2 VNTR was found in 86 autism nuclear families. 25 In contrast, Klauck and colleagues 26 reported preferential transmission of the long variant, while Persico and colleagues 28 and Maestrini and colleagues 27 found no evidence of family-based association.
After screening additional markers, nominally significant transmission disequilibrium was found for several markers in SLC6A4, ranging from promoter 1A to intron 2. HTT SNP9 and HTTSNP11 in the 5Ј flanking region of SLC6A4 exon 1B showed the strongest transmission disequilibrium, suggesting that if there is/are susceptibility variant(s) in autistic disorder in SLC6A4, the 5-HTTLPR is unlikely to be the only variant and may only be in LD with other variants. As expected, the findings were more consistent for SNPs and low complexity VNTRs than for microsatellites presumably due to the higher mutation rate of microsatellites 47 and due to the more dense coverage of SNPs. The patchy pattern of transmission disequilibrium in a small region near exons 1B and 2 is consistent with the finding that SNPs within small DNA fragments such as sequence tagged sites (STSs) are often not in perfect linkage disequilibrium, suggesting gene conversion contributes more to disruption of LD at small distances than recombination contributes. 48, 49 Among markers typed beyond the SLC6A4 region, one SNP (BH-PEN) located approximately 10 kb telomeric of 5-HTTLPR, also showed nominally significant transmission disequilibrium. The BH-PEN polymorphism was identified within exon 12 of the cysteine protease bleomycin hydrolase gene BLMH, 50 and was associated with Alzheimer disease in a case-controlled study. 51 The promoter region, as well as all 15 exons and corresponding exon-intron boundaries of SLC6A4 were screened in autistic disorder. No obviously functional mutation was found in the coding region or exonintron boundaries, but several SNPs were identified. Some of them may be relevant to transcriptional regulation, but this remains to be determined experimentally. In addition, variants in the 5Ј flanking region of exon 1B may be more important in developmental and tissue specific expression of alternative transcripts in which exon 1A is included and exon 1B is or is not included rather than in regulation of transcription potentially initiating at exon 1B. 16, 52 The TDT was nominally significant for several markers in the 5Ј region of SLC6A4, which is consistent with SLC6A4 autism susceptibility variant(s) or variant(s) in another gene in the region (eg BLMH) in autism. Due to linkage disequilibrium between markers, these are not independent measures of transmission disequilibrium. Replication is essential and consistency of replication of a marker or haplotype across samples may help clarify which part of the region is related to autism susceptibility. Alternatively, the pattern of replication may assist in elucidation of a possible phenotype related to autistic disorder that is represented in different proportions in samples ascertained in different ways. Functional studies of the most strongly and consistently associated variants are necessary to test their potential biological significance. Studies underway include: (1) collaborative studies using replication samples; (2) further mutation screening in SLC6A4 that were not covered due to technical difficulties (eg repetititve elements), and flanking regions; (3) typing of more markers in SLC6A4 and flanking regions; (4) study of other neuropsychiatric disorders and quantitative traits in which SLC6A4 is a candidate gene.
